CVS Health Corp (CVS) Receives $85.92 Consensus Target Price from Analysts

CVS Health Corp (NYSE:CVS) has been given a consensus recommendation of “Buy” by the twenty-five ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and fifteen have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $85.92.

CVS has been the topic of a number of research reports. Robert W. Baird reiterated a “hold” rating and set a $77.00 target price on shares of CVS Health in a report on Friday, October 27th. Needham & Company LLC upgraded shares of CVS Health from a “hold” rating to a “buy” rating and increased their target price for the stock from $69.02 to $79.00 in a report on Friday, November 10th. Mizuho set a $90.00 target price on shares of CVS Health and gave the stock a “buy” rating in a report on Tuesday, October 24th. BidaskClub lowered shares of CVS Health from a “hold” rating to a “sell” rating in a report on Friday, August 25th. Finally, Loop Capital initiated coverage on shares of CVS Health in a report on Thursday, August 24th. They set a “hold” rating and a $83.00 target price on the stock.

CVS Health (CVS) traded up $2.04 during trading on Thursday, hitting $73.09. 12,510,000 shares of the stock traded hands, compared to its average volume of 11,050,000. CVS Health has a twelve month low of $66.45 and a twelve month high of $84.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. The stock has a market cap of $74,040.00, a PE ratio of 12.80, a price-to-earnings-growth ratio of 1.37 and a beta of 0.89.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. The firm had revenue of $46.18 billion during the quarter, compared to analysts’ expectations of $46.17 billion. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the company posted $1.64 EPS. research analysts forecast that CVS Health will post 5.9 earnings per share for the current year.

In other CVS Health news, EVP Thomas M. Moriarty sold 90,267 shares of the firm’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $79.61, for a total transaction of $7,186,155.87. Following the transaction, the executive vice president now directly owns 70,102 shares of the company’s stock, valued at approximately $5,580,820.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David M. Denton sold 237,078 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the transaction, the chief financial officer now directly owns 141,096 shares in the company, valued at $11,238,296.40. The disclosure for this sale can be found here. Insiders have sold a total of 714,125 shares of company stock worth $58,119,381 over the last quarter. 0.61% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of the business. AXA raised its position in shares of CVS Health by 14.8% in the third quarter. AXA now owns 681,252 shares of the pharmacy operator’s stock valued at $55,399,000 after buying an additional 87,634 shares during the last quarter. Shelton Capital Management raised its position in shares of CVS Health by 19.4% in the third quarter. Shelton Capital Management now owns 52,860 shares of the pharmacy operator’s stock valued at $4,299,000 after buying an additional 8,574 shares during the last quarter. Chicago Partners Investment Group LLC raised its position in shares of CVS Health by 204.9% in the third quarter. Chicago Partners Investment Group LLC now owns 10,667 shares of the pharmacy operator’s stock valued at $867,000 after buying an additional 7,169 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new position in shares of CVS Health in the third quarter valued at approximately $1,365,000. Finally, Public Employees Retirement System of Ohio raised its position in shares of CVS Health by 0.4% in the third quarter. Public Employees Retirement System of Ohio now owns 728,256 shares of the pharmacy operator’s stock valued at $59,222,000 after buying an additional 2,594 shares during the last quarter. 82.24% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “CVS Health Corp (CVS) Receives $85.92 Consensus Target Price from Analysts” was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.truebluetribune.com/2018/01/02/cvs-health-corp-cvs-receives-85-92-consensus-target-price-from-analysts.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply